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ABSTRACT
The response to endocrine therapy of breast cancer is
not entirely predictable from hormone receptor status
alone since some point mutated or splicing variants of
the estrogen receptor (ER) show altered biological
activities. In order to characterize the activities of all
forms of ER in a heterogeneous breast tumor, a
functional assay in Saccharomyces cerevisiae was
developed. Total RNA isolated from breast cancer cells
and one breast cancer specimen was reverse trans-
cribed and the ER cDNA was amplified by PCR. The
products were then cloned into an expression vector
by in vivo homologous recombination in yeast. The
yeast strain carries a reporter gene (ADE2) coupled to
an estrogen response element. Activation of the
reporter by ER yielded white colonies whereas lack of
ER activity produced red colonies. This permitted the
testing for functionality of individual ER molecules and
subsequent analysis by rescuing of the ER expression
plasmids and complete DNA sequencing. This simple
visual test allows discrimination between wild-type
ER, constitutively active ER and inactive ER.
INTRODUCTION
The content of estrogen receptor α (ER) in breast cancer tissues
is commonly used to identify patients who will most likely
respond to adjuvant antiestrogen treatment and hence have a
lower risk of relapse and a better overall survival than patients
with non-responding tumors (1). However, most tumors that
originally respond to endocrine therapy will develop resistance
during the course of the treatment, although ER is often still
present in the relapse tissues (2). Therefore, resistance to
antiestrogen therapy may not develop due to ER loss but due to
changes in the ER structure and function (3).
As of today, the role of ER variants in the development and
progression of breast cancer is poorly understood and their
clinical significance for therapy failure has not been studied
systematically. Co-expression of several ER mRNA species,
including forms with base pair insertions, transitions and alternate
splicing, have been identified in breast cancer cell lines and
human breast cancer biopsy samples (4). Some of these aberrant
ER forms are present in neoplastic as well as in normal breast
tissues and thus appear to be naturally occurring polymorphisms
(5–8). However, recent data suggest that breast cancer cells
expressing elevated amounts of one of these ER forms, namely
the constitutive activated exon 5 deletion variant, might escape
antiestrogen treatment and continue to proliferate (8).
Presently used diagnostic methods for ER determination do not
discriminate between wild-type and variant receptor forms. The
assessments of ER-induced proteins such as the progesterone
receptor (PR) are commonly used to estimate the biological
activity of the ER in a breast tumor. Consequently, the PR status
of a tumor yields a more reliable prognosis with respect to
response to endocrine therapy than the ER status alone. However,
transcription of the PR gene is not exclusively regulated by the ER
(9–12). Thus, it seems likely that a method distinguishing
between functional and non-functional ER would give more
information for the selection of the appropriate adjuvant therapy.
The use of homologous recombination in yeast allows efficient
cloning of PCR products directly in vivo. An assay published
earlier uses a technique, called functional analysis of separated
alleles in yeast (FASAY), for the investigation of p53 functionality
in tissue samples (13). Additionally, Metzger et al. demonstrated
that the ER can be expressed in yeast and is indistinguishable
from the ER expressed in human cells (14). Activation of
transcription in the yeast system is strictly hormone-dependent.
We combined the two findings using ADE2 as a reporter gene in
yeast and established a new screening method to test for ER
functionality. This assay allows determination of the ratio of
functional, non-functional and constitutive activated ERs in
tumor biopsies. Individual ERs, wild-type or mutant, can be
rescued from the yeast colonies and further investigated by
sequence analysis.
MATERIALS AND METHODS
Cell line and tumor biopsy
MCF-7 breast cancer cells (Mason Research Institute, Rockville,
MD) were grown in a humidified atmosphere, containing 5%
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CO2, in IMEM-ZO (improved minimal essential medium–zinc
option; Biological Industries, Kibbutz Beth Haemak, Israel) as
described (15), supplemented with 5% (v/v) fetal calf serum,
10 mM HEPES (pH 7.3), 5 µg/ml insulin (Eli Lilly, Indianapolis,
IN), 10 U/ml penicillin, 10 U/ml streptomycin, 2 mM L-glutamine
and 13.3 µM phenol red. The medium was switched to serum-free
medium after cells reached ∼80% confluency (16). After 2 days,
cells were harvested by trypsinization, washed three times with
phosphate-buffered saline (PBS), pelleted by centrifugation and
stored at –70C. The primary tumor specimen was obtained from
the tissue collection of the Stiftung Tumorbank Basel and
originates from a breast cancer patient who had been treated
surgically by wide local excision. The biopsy was shock frozen
in liquid nitrogen and stored at –70C. ER and PR were
determined quantitatively in cytosol preparations of the tissue
sample and MCF-7 cells using enzyme immunoassay monoclonal
kits (Abbott, Chicago, IL).
Total RNA isolation and reverse transcription
Total RNA was extracted from 106 cells or 30 mg of pulverized
tissue with a RNeasy kit (Qiagen, Hilden, Germany). RNA
quantification was performed by mixing 2 µl RNA with 200 µl
DEPC-treated water and SYBR Green II (Molecular Probes Inc.,
Eugene, OR) in a 96-well plate. Yeast total RNA (Sigma,
St Louis, MO) ranging from 5 ng to 12.5 µg was used as a
standard. After 30 min incubation at room temperature fluorescence
was measured with a Fluorostar plate reader (Perkin Elmer,
Foster City, CA). For cDNA synthesis, 1 µg RNA was diluted in
DEPC-treated water to a final volume of 12.5 µl, denatured at
70C for 2 min and subsequently chilled on ice. Reverse
transcription was performed in the presence of 0.5 mM dATP,
0.5 mM dCTP, 0.5 mM dTTP, 0.5 mM dGTP, 50 mM Tris–HCl
(pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 1 U/µl
ribonuclease inhibitor (RNAsin; Promega, Madison, WI),
20 pmol random hexamer primers and 200 U M-MLV reverse
transcriptase (Promega, Madison, WI) for 1 h at 42C. The
reaction was terminated by heating for 5 min at 94C. A
quantitative and qualitative control of the obtained cDNA was
performed as described earlier (8).
Primers and PCR conditions
cDNA abundance was calculated according to the amount of the
control PCR product (glyceraldehyde-3-phosphate dehydrogenase).
Equal amounts of cDNA were used for PCR amplification of the
ER coding sequences with primer p1 (5′-ATG ACC ATG ACC
CTC CAC ACC AAA G-3′, nt 233–257, codons 1–9) and primer
p2 (5′-CTC AGA CTG TGG CAG GGA AAC CCT-3′,
nt 1998–2021, codons 589–596). PCR amplifications were
performed with 0.625 U of Taq DNA polymerase (Qiagen,
Hilden, Germany) in a total volume of 25 µl, in PCR buffer
supplemented with Q-Solution (Qiagen, Hilden, Germany) and
1 mM MgCl2, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dGTP,
0.2 mM dCTP and 0.3 µM each primer. Each PCR consisted of
36 cycles (12 cycles with 1 min at 94C, 4 min at 68C, followed
by 24 cycles with 1 min at 94C, 4 min, plus a time increase of
15 s per additional cycle at 68C). Conditions for PCR
amplifications with 1.625 U of cloned Pfu DNA polymerase
(Stratagene Cloning Systems, La Jolla, CA) were similar except
that each PCR consisted of 40 cycles (45 s at 95C, 1 min at 60C,
4 min at 72C). PCR products were stained with SYBR Green I
nucleic acid stain (Molecular Probes Inc., Eugene, OR) and then
separated on 1% agarose gels by electrophoresis. The concentrations
of the amplification products (1789 bp) were evaluated by
densitometric measurements. Quantification of the signals was
performed using the Molecular Analyst software (BioRad,
Hercules, CA).
Plasmids
Plasmid pU/ERE-Ade2 was constructed by substituting a single
estrogen response element (ERE) for the p53 binding sites in
plasmid pLS210 (17). The key features of plasmid pU/ERE-Ade2
are: an ERE upstream of the minimal CYC1 promoter driving the
expression of ADE2 and the URA3 marker. The β-galactosidase
reporter plasmid pUC∆SS-ERE has been described earlier (18).
The gap repair vector pG/hER∆ was derived from the expression
vector pG/ER(G) (19) by deleting the NotI–PflMI fragment
comprising codons 68–503 of ER; the gap repair vector retains a
unique NotI site at the junction of the first 200 bp and the last
280 bp of the ER coding sequence at the 5′- and 3′-ends,
respectively. Both pG/ER(G) and pG/hER∆ are high copy
number yeast episomes with the 2µ replicon and the TRP1
marker. The vector pG/hER∆ was prepared for transformation by
digestion with NotI, filling the cohesive ends with Klenow
fragment of DNA polymerase I and dephosphorylation of the
resulting blunt ends with shrimp alkaline phosphatase (Boehringer
Mannheim, Germany). The plasmid pG/ER∆5 harbors the human
ER exon 5 deletion variant.
Yeast strains
The Saccharomyces cerevisiae strain YPH250 (MATa ade2-101o
his3-∆200 leu2-∆1 lys2-801a trp1-∆1 ura3-52) (20) was used as
parent strain. The ERE–ADE2 construct pU/ERE-Ade2 was
linearized with BstBI within the URA3 gene and integrated into
the ura3 locus of YPH250 to yield strain DP160 (MATa ade2-101o
his3-∆200 leu2-∆1 lys2-801a trp1-∆1 ura3-52 URA3::ERE-ADE2
[pU/ERE-Ade2]). Strain DP161 (MATa ade2-101o his3-∆200
leu2-∆1 lys2-801a trp1-∆1 ura3-52 URA3::ERE-ade2 [pU/ERE-
Ade2]/hER-2µ-TRP1 [pG/ER(G)]) was derived from DP160 by
the introduction of plasmid pG/ER(G).
Growth media
Handling of strains has been described by others (17). YEPD
(Gibco-BRL Life Technologies, Paisley, UK) was used for the
culturing of yeast. DP160 was routinely cultured on medium
supplemented with adenine (200 µg/ml) to avoid selection of
spontaneous suppressors of the endogenous mutant ade2 locus.
Solid media for red/white screening consisted of 2% D-glucose,
0.67% yeast nitrogen base without amino acids (DIFCO Labora-
tories, Detroit, MI), 2% agar, all amino acids except uracil and
tryptophan, plus limiting amounts of adenine (5 µg/ml) and
optionally 100 nM 17-β-estradiol (Sigma, St Louis, MO).
Transformation of yeast
Plasmids were introduced into yeast by the LiAc/PEG method
(21). Aliquots of 50 µl of yeast cells were mixed with 100 µg
heat-denatured carrier DNA (sonicated single-strand salmon
sperm DNA; Stratagene), 100 ng of linearized gap repair vector
pG/hER∆ and 100 ng of unpurified PCR products. After
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transformation 50 µl were spread on appropriate minimal
medium for selection of plasmids (synthetic complete –ura –trp,
5 µg/ml adenine). After incubation for 72 h at 30C and 12 h at
4C colonies were scored for color. Subsequently, colonies were
replica plated (Accutran replica plater; Schleicher & Schuell,
Switzerland) on selective medium containing 100 nM estradiol
(Sigma, St Louis, MO), incubated for 36 h at 30C and 12 h at
4C and colonies were scored again for color. With each series of
transformation a positive control [300 ng of plasmid pG/ER(G)]
and a negative control (100 ng linearized gap repair vector) were
included.
Western blot analysis
One milliliter of an overnight yeast culture (DP161) was
centrifuged and washed with PBS. Cells were lysed by vortexing
for 3 min with acid-washed glass beads in 150 µl TEGMo-buffer
(10 mM Tris–HCl pH 7.4, 1.5 mM EDTA, 5 mM disodium
molybdate, 10% glycerol, 1 mM monothioglycerol). Lysates of
30 × 106 MCF-7 cells or 30 mg tissue were prepared in TEGMo
buffer by mechanical disruption. ER was immunoprecipitated
with a polyclonal antibody G-20 (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) directed against the hinge region of the ERα and
protein G–Sepharose 4 Fast Flow beads (Pharmacia, Uppsala,
Sweden). After an incubation of 2 h at room temperature, the
immunoprecipitates were washed and ER was eluted. Eluates
were used for analysis by 10% SDS–PAGE and transferred to
nitrocellulose membranes by electroblotting. Blots on nitrocellulose
membranes (Immobilon; Millipore, Bedford, MA) were probed
with a mouse monoclonal antibody against human ER (DAKO-ER
1D5; Dako A/S, Glostrup, Denmark) and alkaline phosphatase-
conjugated secondary antibodies (goat anti-mouse IgG; Santa
Cruz Biotechnology Inc., Santa Cruz, CA). Detection was
performed with the chemiluminescence western blotting kit
(BioRad Laboratories, Hercules, CA).
DNA rescue
Yeast colonies were picked from the plate and individually grown
overnight in microtiter plates containing 200 µl YEPD medium.
Subsequently, cells were pelleted and lysed with 10 U of
Zymolase (ICN Biomedicals Inc., Aurora, OH) in the presence of
50 mM β-mercaptoethanol, 10 mM EDTA and 50 mM Tris–HCl
(pH 7.5) in a final volume of 240 µl for 30 min at 37C. Plasmid
DNA was isolated using the QIAprep Spin Plasmid kit (Qiagen,
Hilden, Germany). Plasmids were transfected into XL-1 Blue
bacteria by electroporation. Minipreparation of plasmids was
carried out using the QIAprep Spin Plasmid kit (Qiagen, Hilden,
Germany). The isolated plasmids were cut with BamHI (New
England Biolabs, Beverly, MA), restriction products were stained
with SYBR Green I nucleic acid stain (Molecular Probes Inc.,
Eugene, OR) and separated on a 1% agarose gel by electrophoresis.
Sequence analysis
Inserts of the rescued plasmids were amplified by PCR (see
Primers and PCR conditions) and purified PCR products were
sequenced. Cycle sequencing was performed with 30–50 ng
purified PCR product using the ABI Prism Big Dye terminator
cycle sequencing ready reaction kit (Applied Biosystems Division,
Perkin Elmer, Foster City, CA). Sequences were analyzed on an
ABI 310 automated sequencer and assembled with the Auto
Assembler software (Perkin Elmer, Foster City, CA).
RESULTS
Control of ADE2 gene expression in the yeast
Saccharomyces cerevisiae
In the S.cerevisiae strain YPH250 (20) the endogenous ADE2
gene is mutated and an ERE-controlled ADE2 gene (reporter) was
stably introduced by chromosomal integration at the URA3 locus.
Thus, the activation of the reporter gene is dependent on the
activity of ER expressed in yeast. The ADE2 gene encodes an
enzyme of the adenine biosynthesis pathway. Lack of the enzyme
yields an accumulation of a red colored intermediate metabolite
of adenine metabolism (22). Therefore, colonies grown on an
appropriate medium containing limiting amounts of adenine turn
red (23). The wild-type ER expression vector was introduced by
transformation, yielding the yeast strain DP161. The estradiol-
activated wild-type ER forms homodimers which bind to ERE
and stimulate transcription of the reporter gene resulting in white
colonies, whereas lack of ER activity yielded red colonies.
Without addition of estradiol all yeast colonies were red whereas
upon addition of 1 nM estradiol to the medium all yeast colonies
turned white (Fig. 1). This sensitivity for estradiol was confirmed
by a β-galactosidase assay performed with the same yeast strain
containing a β-galactosidase reporter plasmid (pUC∆SS-ERE;
18; results not shown). Furthermore, co-transformation of gap
repair vector and PCR products obtained from a plasmid
harboring the ER exon 5 deletion variant (pG/ER∆5) produced
exclusively white colonies in the presence and absence of
estradiol, indicating that constitutive active forms of the receptor
show the expected phenotype in the assay (data not shown). These
findings indicate that the ADE2 reporter in yeast was able to
visualize the functionality of the wild-type ER in a strictly
hormone-dependent manner.
Expression of ER in yeast
The yeast strain DP161 expressed 195 fmol ER/mg cytosolic
protein, as determined by enzyme immunoassay. Figure 2 shows
a western blot of cytosol extracts of the yeast strain DP161, of the
breast cancer cell line MCF-7 and of a breast cancer tissue.
Figure 2 confirms that the human ER is expressed in yeast at
amounts similar to cell lines and that the 65 kDa molecular weight
of the ER protein in yeast corresponds to the ER expressed in
mammalian cells (24–26).
Gap repair assay for the functional screening of ER
A schematic diagram of the method is depicted in Figure 3. Total
RNA was isolated from frozen samples and reverse transcribed.
With the obtained cDNA, PCR amplification of the ER coding
sequence was performed. The unpurified PCR products were
transformed into yeast cells together with a linearized gap repair
expression vector. ER coding sequences were integrated into the
expression vector by homologous recombination in yeast generating
circular plasmids. Yeast colonies growing on selective medium
(ura–, trp–, limiting adenine) repaired their ER expression
plasmid resulting in expression of the ER proteins in yeast. By
transferring the transformed colonies from medium lacking
estrogen to estrogen-containing medium, three different pheno-
types can be expected (Table 1). Colonies that are red on medium
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Figure 1. The ADE2 reporter is estrogen-dependent. In the recipient yeast strain, the endogenous ADE2 has been inactivated and, subsequently, an ERE-controlled
ADE2 gene (reporter) has been introduced at the URA-3 locus. The wild-type ER was introduced and cells were grown on indicator medium containing various amounts
of the ligand estradiol. Absence of ADE2 expression led to the formation of red colonies on medium with limiting exogenous adenine. Addition of estradiol to the
culture medium activated the ER and produced white colonies.
Figure 2. Western blot of ER from different sources. Aliquots of 50 µg total
protein each from cytosolic extracts of MCF-7, one human breast cancer tissue
sample and from yeast strain DP161 were separated by 10% SDS–PAGE.
Western blot analysis was performed using a monoclonal antibody directed
against the hinge region of the ER (wild-type ER, Mr 65 000).
lacking estrogen and turn white in the presence of estrogen
represent wild-type ER. Colonies that are white without estrogen
and stay white in the presence of estrogen contain constitutively
active ER. Colonies that are red in the presence and absence of
estrogen contain either non-functional ER or self-ligated empty
vectors. A fourth putative phenotype, an ER that is active in the
absence of hormone but becomes inactive in the presence of
hormone, is not expected to be found.
Table 1. Predicted phenotypes of yeast colonies
Without estradiol With estradiol
White phenotype Red phenotype
Red phenotype Wild-type Non-functional ER
Gap repair vector
(background)
White phenotype Constitutively active ER ?
Controls for the assay
Co-transformation of 25 ng gap repair vector with 25 ng of
unpurified PCR product gave rise to 200–600 colonies on
selective medium. Controls consisting of linearized gap repair
vector only (negative control) or wild-type ER plasmid (positive
control) were transformed with each series. The vector alone
produced little background (1–2%) whereas the wild-type ER
Figure 3. Functional display of ER molecules in yeast. For explanations see text.
produced exclusively red and, after replica plating on medium
containing estradiol, exclusively white colonies. To test for false
red or false white colonies due to PCR-induced mutations,
wild-type ER from plasmid pHEGO (27) was amplified with Taq
DNA polymerase or with a polymerase with proofreading ability
(Pfu DNA polymerase). Different amounts (0.13, 0.013 and
0.0013 pg) of template DNA were used for the PCR reaction
(Table 2). From these experiments the amount of ER template
cDNA used in the assays was estimated and yielded a value of
∼0.1 pg, since we obtained amounts of PCR products (2.5 µg with
Taq DNA polymerase) similar to the reaction with 0.13 pg
wild-type ER. By using 10–100 times less template in the PCR
reaction, the number of errors introduced by the polymerases
could in theory increase. Therefore, yeast was transformed with
100 ng of unpurified products from the PCRs with different
amounts of template and as a control 100 ng of wild-type ER cut
from pHEGO. In all cases, on medium without estradiol all
colonies were red whereas after replica plating on medium
containing estradiol, 95% or more of the colonies turned white
(Table 2). The colonies with religated gap repair vector are
included in this 5% background. The experiment was repeated
three times and standard errors below 1% were observed. This
indicates that the error rate resulting from the PCR reaction
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Figure 4. Restriction products of rescued ER clones originating from MCF-7
cells. A selection of plasmids derived from individual yeast colonies were cut
with BamHI and separated on 1% agarose gels. Restriction products represent
vector and their respective ER inserts.
accounted for only a few colonies per transformation plate and
produced only inactive phenotypes. The use of Taq polymerase
resulted in a slightly higher apparent error rate than with Pfu
(Table 2). The differences in error rate between the two
polymerases were, however, small and indicated that Taq
polymerase with its higher efficiency can be used for the assay.
Transformation of 500 ng of a PCR product that was not ER
related (erbB4 fragment) yielded the same rate of background
colonies indicating that foreign DNA was not introduced into the
gap repair vector by homologous recombination (not shown). The
assay was then tested with ER-positive MCF-7 cells. After
transformation, a selection of colonies was grown and their
plasmids were rescued. Each individual yeast colony contained
only one type of ER insert as tested by restriction digestion
(Fig. 4). Thus, the individual yeast colonies contained ER
plasmids derived from a single recombination event indicating an
efficient segregation of the different PCR products. Reamplifications
of these individual ER inserts were performed and their
phenotypes were confirmed by retesting these ER variants with
the yeast bioassay. Additionally, size variations of the inserts
might originate from different ER variants (Fig. 4).
Table 2. Rate of false phenotypes
DNA Input Without estradiol With estradiol
polymerase DNAa (pg)  (red) (%) (white)b (%)
Taq 0.13 100 96.3 ± 0.9
0.013 100 95.0 ± 0.8
0.0013 100 95.0 ± 0.3
Pfu 1.3 100 98.8 ± 0.2
0.13 100 98.9 ± 0.6
0.013 100 96.3 ± 0.7
Controlc 100 0
Different amounts of wild-type ER as templates were amplified with Taq or with
Pfu DNA polymerases. Yeast was transformed with 100 ng of the respective,
unpurified PCR products and 100 ng of wild-type ER cut from pHEGO (control),
respectively. On medium without estradiol all colonies were red whereas after
replica plating on medium containing estradiol, 95% or more of the colonies
turned white.
aTemplate, wild-type coding sequence of ER.
bMean percentage of white colonies ± SD (n = 3).
c100 pg of ER fragment, isolated by restriction digestion from plasmid pHEGO.
ER heterogeneity in MCF-7 breast cancer cells and in one
human breast cancer specimen
Transformations of ER PCR products from both the MCF-7 cells
and one human breast cancer tissue resulted in a similar mixture
of different phenotypes (Figs 5A and 6A). The percentages of
functional, non-functional and constitutive active ERs in these
samples were calculated and are shown in Table 3. Using a cut-off
value of 20 fmol ER/mg cytosolic protein, both the MCF-7 cells
and the primary breast cancer sample were defined as ER-positive
(156 and 181 fmol ER/mg cytosolic protein, respectively).
However, our yeast assay revealed that only 33% of ER
molecules in MCF-7 cells and only 40% in the tissue sample were
responding to estrogen with transcriptional activity (Table 3).
Table 3. ER phenotypes in the MCF-7 breast cancer cell line and one breast
cancer specimen
Sample Constitutively active Inactive Wild-type
(%) (%) (%)
MCF-7 10 57 33
Breast cancer specimen 6 54 40
ER profile in MCF-7 cells and a human breast cancer tissue
Plasmids from several randomly picked yeast colonies were
isolated and analyzed by PCR and DNA sequencing. A series of
PCR products of a yeast transformation assay with MCF-7 cDNA
is shown in Figure 5B. Functional ER (from white colonies in the
presence of estradiol; lanes 1–12) mainly showed the size of the
wild-type PCR product. The plasmid inserts with a size that deviated
from the wild-type size were then analyzed by sequencing. One PCR
product (lane 10) was identified as the exon 5 deletion variant,
appearing as a constitutively active phenotype in the functional
assay. Analysis of a PCR product slightly larger in size than the
wild-type (lane 12) revealed an incomplete duplication of exon 4
resulting in the translation of a truncated protein due to a
frameshift. In the yeast functional bioassay this truncated protein
was also constitutively active. Rescued non-functional ERs (from
red colonies in the presence of estradiol; Fig. 5B, lanes 13–26)
were either of wild-type size, corresponding most likely to
inactive ER mutants, or of sizes different from the wild-type,
indicating the presence of inactive ER splicing variants. Lane 24
corresponds to an empty self-religated gap repair vector.
Sequence analysis of PCR products smaller than the wild-type
size revealed that they were all deletion variants (lane 17, exon 4
deletion; lane 20, exon 3 deletion; lane 21, exon 6 deletion)
containing frameshifts which lead to non-functional truncated
proteins. Two non-functional ER with wild-type size were
sequenced and contained an ER with an insertion of an additional
cytosine (Fig. 5B, lane 16) at position 1202 (codon 324) or an ER
with a deletion of one adenine (Fig. 5B, lane 22) at position 699
(codon 156). These point mutations changed the reading frame
and resulted in truncated non-functional proteins. These findings
demonstrate that the assay is able to detect inactivating point
mutations.
The human breast cancer sample showed a similar variety in
rescued ER products (Fig. 6). In the series of ER variants derived
from the human breast cancer specimen, a non-functional
splicing variant, namely the exon 7 deletion variant, was
identified twice (Fig. 6B, lane 1 and 3).
DISCUSSION
FASAY (13) was recently used for the investigation of ER in
breast cancer biopsies (28). However, this approach was based on
a growth selection for yeast colonies with functional ER. Yeast
colonies containing non-functional ER molecules were lost on
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Figure 5. ER profile of MCF-7 cells. (A) Colonies transformed with gap repair vector and MCF-7 ER PCR products. Colonies were grown on indicator medium
containing 100 nM estradiol (phenotype score, Table 3). (B) ER inserts obtained from yeast colonies transformed with MCF-7 ER PCR products. Lanes 1–12, a
selection of rescued functionally intact ER; lanes 13–26, a selection of non-functional ER. Lane 24 shows the band corresponding to an empty gap repair vector
(background). Indicated by the arrow is the wild-type ER size. An insertion of a C (lane 16) and a deletion of an A (lane 22) changed the reading frame and resulted
in truncated, non-functional proteins.
Figure 6. ER profile of a primary human breast tumor. (A) Colonies transformed with gap repair vector and ER PCR products from a human primary breast cancer
sample. Colonies were grown on indicator medium containing 100 nM estradiol (phenotype score, Table 3). (B) ER inserts obtained from yeast colonies transformed
with ER PCR products from the human breast cancer specimen showing a selection of functional, non-functional and constitutively active ERs.
selective plates. In contrast, the assay described in this report takes
advantage of the adenine biosynthesis system in S.cerevisiae and the
ADE2 gene as a reporter (17) coupled to an ERE. Activation of
gene transcription led to the formation of white colonies whereas
lack of activation produced red yeast colonies. Combination of
this system with gap repair and RT–PCR allowed a simple visual
distinction between hormone-dependent (wild-type), non-functional
and constitutively active ER. Thus, this assay allows the
investigation of ER and its variant forms in human breast tumors
since the PCR amplification products reflected quantity and type
of ER receptor in the tumor. Consequently, the segregation of the
amplification products into individual yeast colonies resulted in
a population of yeast colonies representing the ER mRNA of the
original cells or tumors. However, ER variants deleted in the
primer binding sites will not be amplified and therefore not
detected by the yeast assay. Furthermore, point mutations in the
recombination regions of 200 bp at the 5′-end and 280 bp at the
3′-end of the coding region will not be detected in all cases and
if detected their abundance might be under-represented in the
yeast colonies.
Testing the antiestrogens tamoxifen and ICI 182780 has not
been possible in any in vivo yeast assay described so far, including
the one presented here (29–32). Additions of various concentrations
of these antiestrogens to yeast medium were also tested in a yeast
β-galactosidase assay (not shown). Neither the partial antagonists
tamoxifen and hydroxytamoxifen nor the full antagonist ICI
182780 inhibited the action of estradiol. On the contrary, the
antiestrogens tamoxifen and hydroxytamoxifen acted as partial
agonists for the ER as also demonstrated by others (29,31,33).
Explanations for the failure to inhibit estrogen activity with
antiestrogens might be insufficient uptake of these compounds
into the yeast cells, metabolic changes of the compounds in yeast
cells resulting in the formation of agonists, lack of co-repressor
recruitment or other yeast-specific mechanisms (34). Further
investigations are needed to enable the use of antiestrogens in
yeast assays.
The findings with MCF-7 breast cancer cells demonstrate that
a large heterogeneity with respect to ER is present in tumor cells.
MCF-7 cells are in principle clonal and therefore should show a
homogeneous phenotype. However, whether the polymorphism
found is due to the prevalence of ER variants in single cells or
derives from ER variants from different cells remains to be
investigated. The yeast assay allowed detection of novel mutant
ER forms as well as previously described mutations or splice
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variants (Fig. 6C). Additionally, the biological function of these
forms could be easily determined. For example, a duplication of
exon 4 resulting in a constitutively active ER was found.
Duplications of whole exons of the ER sequence have been
described earlier (35) although their functional effects were not
addressed. The phenotype of some splicing variants could be
confirmed, such as the exon 7 deletion variant that lacks the
dimerization ability of the receptor and therefore is not capable of
binding to DNA. We also detected two novel point mutations
(codon 324, 1202insC; codon 156, 699delA). The fact that the
resulting truncated ER proteins have no intact DNA-binding
domain and have lost their C-terminal transactivation domain makes
them possible candidates for dominant negative ERs (36). The
possibility that these point mutated ERs might be artifacts due to
PCR amplification is unlikely for several reasons: (i) the Taq DNA
polymerase-produced mutations are rather misincorporations than
deletions or insertions; (ii) Taq has an error rate of 1.8–2 ×
10–5/nucleotide/cycle (37,38) and under the conditions we used,
this leads to only a few percent inactive phenotypes (Table 2);
(iii) under the conditions used, false non-functional ERs represent
only a small proportion and are mostly due to background (religated
empty gap repair vector). Potentially important inactivating
mutations are visualized in the assay (red colonies) whereas
functionally silent mutations appear as wild-type phenotypes.
Furthermore, the assay gives information about the frequency of
non-functional ER forms in tumors and therefore determines the
predominant phenotype of ER in a specimen.
To this date ER variants have been investigated mainly at the
DNA and RNA/cDNA levels. Therefore, it is still not clear
whether the identified mutations or splice variants are actually
translated into proteins and to what extent. The yeast assay allows
the investigation of ER variants at the protein level since the
function of the protein is measured. Approximately 200 fmol/mg
cytosolic protein are expressed in yeast (Fig. 2) which corresponds
to the average ER concentration in breast cancer tissues (39,40).
The biological activity of the ER is routinely assayed by the
determination of ER-induced proteins. The tumor sample tested
with the functional assay was positive with respect to PR and ER
as determined by enzyme immunoassay, indicating a population
of biologically active ER. However, the yeast bioassay revealed
that the tumor sample contained 54% non-functional ER. These
findings suggest that variant mRNAs encoding truncated ER
proteins may contribute to misleading determinations if the
antibodies used for detection target only the N- or C-terminus (41).
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